

19. ELN Symposium with 22. KNL Symposium

Congress Center Rosengarten, Mannheim, April 18, 2023, 8:00-20:00

WP sessions 1-4 (Mahler 1)		Chairs/Contributors
8:00 - 9:30	Session 1: WP5 AML 1	C. Röllig, G. Ossenkoppele
30'	Update ELN-DAVID-MRD AML	J. Cloos, M. Heuser
35'	IMPACT R/R AML (EU project) Immunotherapy	G. Martinelli
10'	DC vaccination	A. van de Loosdrecht
15'	Novel CAR-T cell approaches in AML	M. Hudecek
9:30 - 9:45	Coffee Break	
9:45 - 11:15	Session 2: WP5 AML 2	C. Röllig, G. Ossenkoppele
60'	Overview European AML trials in first line	Representants of AML trial group
7.5'	PETHEMA	P. Montesinos
7.5'	FIL0	C. Recher
7.5'	ALFA	H. Dombret
7.5'	PALG-AML	A. Wierzbowska
7.5'	GIMEMA	A. Venditti
7.5'	NCRI	C. Craddock
7.5'	AMLSG-HOVON	G. Ossenkoppele
7.5'	SAL-AMLCG	C. Röllig
10'	MRD as surrogate for survival (HARMONY)	J. Tettero
20'	Update recommendation for the definition of fitness	A. Venditti
11:15 - 11:30	Break	
11:30 - 13:00	Session 3: HARMONY/HARMONY PLUS	J.M. Hernandez, L. Bullinger
5'	HARMONY and HARMONY Plus – General Update	J.M. Hernández
10'	AML Data visualization on the HARMONY Platform	L. Bullinger, A Hernández
5'	Discussion	
35'	HARMONY Results - CLL, ALL, MDS	L. Scarfo, V. Santini
15'	HARMONY PLUS - CML projects update	A. Hochhaus, T. Dahlen, M. Pfirrmann
10'	The HARMONY Foundation – Value for public organisations	K. Döhner
5'	Discussion	
5'	Next steps	J.M. Hernandez, L. Bullinger
13:00 - 14:00	Lunch	
14:00 - 15:30	Session 4: WP8 MDS	L. Malcovati, M. Mittelman
2'	Introduction, minutes previous meeting	L. Malcovati, M. Mittelman
5'	Report EUMDS Registry	L. Malcovati, C. van Marrewijk
	a) General overview EUMDS	
	b) Progress and highlights of sub studies and MDS-RIGHT activities	
20'	- Thrombotic events in LR-MDS	M. Mittelman
	- Causes of death	K. Mađry
8'	HARMONY – projects in MDS	J.M. Hernandez
8'	EuroBloodNet – MDS activities	L. Malcovati on behalf of P. Fenaux
15'	ELN iMDS Flow Working Group	A. van de Loosdrecht

- ELN recommendations of flowcytometry in MDS 2023

MDS-Hub – update

5'	- International guideline development	L. Malcovati
15'	- Progress WG1: Diagnosis & Prognosis	R. Hasserjian
10'	General discussion	All
2'	Closure of the meeting	L. Malcovati, M. Mittelman

WP sessions 5-8 (Mahler 2)

Chairs/Contributors

8:00 - 9:30	Session 5: WP6 ALL	D. Hoelzer, S. Chiaretti
	Immunotherapy in B-lineage ALL	
	Blinatumomab frontline HOVON Trial	A. Rijneveld
	Inotuzumab ozogamicin in MRD+ ALL	G. Marconi
	BH3 mimetics in ALL	
	Blina-Venetoclax in R/R or MRD+ ALL	C. Baldus
	Real-life use of Venetoclax-Navitoclax	F. Malfona
	Ph+/Ph-like ALL	
	Update of the D-ALBA Trial	S. Chiaretti
	Allo-SCT in CR1, particularly in Ph+/Ph-like ALL	J. Ribera
	T-ALL Progress on T-ALL: GMALL experience	N. Gökbüget
9:30 - 9:45	Coffee Break	
9:45 - 11:15	Session 6: WP4 CML	L. Stenke, F. Guilhot, A. Hochhaus
15'	AlloHCT in patients with CP-CML in the era of 3G TKI: A retrospective study by the chronic malignancies WP of the EBMT	Y. Chalandon
15'	Steric structure of BCR-ABL1 and prediction of response to asciminib according to the mutation profile. A EUTOS project	O. Hantschel
15'	The HARMONY registry on Treatment Free Remission	T. Dahlén
15'	The HARMONY genomic registry on CML: Clonal hierarchy	T. Ernst
15'	WHO classification 2022 on CML	A. Hochhaus
15'	Management of children and adolescents with CML in blast phase: International pediatric CML expert panel recommendations	M. Metzler
11:15 - 11:30	Break	
11:30 - 13:00	Session 7: WP9 MPN	T. Barbui
	Management of Philadelphia-negative MPN in pregnancy; Evidence and consensus-based recommendations by ELN international working group	M. Griesshammer
	A machine learning approach using bone marrow trephine samples in MPNs	D. Royston
	How to categorize “Myelofibrosis-Type Megakaryocyte Dysplasia (MTMD)” in the realm of myeloproliferative neoplasms	G. Barosi
	Detrimental Consequences of Phlebotomies-Induced Iron Deficiency on Thromboses in Polycythemia Vera”? Ernest-3. ELN observational study in contemporary patients with myelofibrosis	J. Prchal
	Low-risk PV: management with phlebotomies and indications for cytoreduction	T. Barbui
	Study proposal for acute leukemia arising in MPN	A. Alvarez-Larran
	Study proposal on MPN with non-canonical mutations in JAK2, CALR and MPL	F. Mannelli
		G. Carreno
13:00 - 14:00	Lunch	
14:00 - 15:30	Session 8: WP7 CLL	P. Ghia, A. Rawstron, L. Scarfò
10'	Welcome and Introduction	P. Ghia

20'	Special Lecture. A large fraction of trisomy 12, 17p and 11q CLL cases carry unidentified microdeletions of miR-15a/16-1	C. Croce
10'	Ongoing project. Other malignancies in the history of CLL	L. Scarfò
10'	Ongoing project. The evolving landscape of COVID-19 in patients with CLL through waves and post-COVID condition	A. Visentin
10'	Ongoing project. MRD certification	A. Rawstron
10'	New projects. An overview	P. Ghia
20'	Discussion	

WP sessions 9-12 (Mahler 3)

8:00 - 9:30		Chairs/Contributors
	Session 9: WP14 Transplantation	D. Niederwieser, L. Garderet, W. Jędrzejczak
6.5'	Information on published project	
	AML intergroup study (publication accepted)	D. Niederwieser
6.5'	Global AML Utilization	M. Tokaz (TBC)
	Current projects	
10'	The Waustim project (age, race and equity issues)	L. Garderet
	Randomized European HSCT study in patients >60 a with AML	
6.5'	CR1 and a matched donor (ELN-EBMT) (manuscript ready)	D. Niederwieser
6.5'	GvHD app	D. Neumann
6.5'	Internet-based Global Transplant Registry GTR	D. Neumann
6.5'	Global transplant survey up to 2018	D. Niederwieser
6.5'	time sequential therapy in HSCT	H.J. Kolb
6.5'	AML R/R HSCT protocols	G. Martinelli
6.5'	The HUP Ukraine (Network of ASH, ELN, WBMT, DGHO...)	D. Niederwieser
	New projects	
6.5'	Worldwide utilization of HSCT in CML + outcome registry	D. Niederwieser
6.5'	Outcome registry and utilization of AML worldwide	D. Niederwieser
8.5'	General discussion (AI; GvHD recommendations)	all
9:30 - 9:45	Coffee Break	
9.45 – 11.15	Session 10: WP10 Immunophenotyping	M.C. Béné, G. Zini
15'	The role of morphology in the light of the new proposed classifications WHO5th and ICC	G. Zini
5'	Discussion	
10'	News about the morphology faculty	G. Zini
15'	A new prognostic flow assay for AML using post induction data	C. Row
5'	Discussion	
15'	Capsule of the recent ELN papers on MDS	W. Kern
5'	Discussion	
12'	Capsule of the recent ELN papers on AML MRD	M.C. Béné
3'	Discussion	
5'	News about the IVDR	M.C. Béné
	Break	
11:30 - 13:00	Session 11: WP11 Cytogenetics	I. Summerer, B. Espinet
15'	The role of cytogenetics in the WHO classification 2022	B. Balk
15'	Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations	B. Espinet
15'	Cytogenetics as the basis for the detection of BCL11B deregulation in a distinct subgroup of T-lymphoid and myeloid immature acute leukemia	C. Mecucci
15'	A gene expression classifier (ALLCatchR) allows the classification of B-ALL according to WHO and ICC 2022	T. Beder
15'	Toolbox of methods for the detection of chromosomal/genetic alterations	I. Summerer
13:00 - 14:00	Lunch	

14:00 - 15:30	Session 12: WP12/13 MRD/NGS Genomes and AI: a diagnosis in one step? WGS for ALL CEBPA mutations in AML: A complex issue FLT3 MRD in AML
	WP session 13 (Seminarraum 3.9)
11:30 - 13:00	Session 13: WP17 Biometry and Epidemiology
5'	Welcome and overview
25'	Randomized or single-arm trials? Ethical and methodological issues in the era of targeted therapies
25'	Propensity scores - opportunities and obstacles
25'	Turning data into knowledge - managing clinical data in Excel and conducting basic analysis using SPSS
10'	Summary

Plenary Sessions (Mahler1)

16:00 - 17:30	Session 14: General Assembly and Summary reports
20'	General Assembly
5'	WP4 (CML)
5'	WP5 (AML 1)
5'	WP5 (AML 2)
5'	HARMONY
5'	WP6 (ALL)
5'	WP7 (CLL)
5'	WP8 (MDS)
5'	WP9 (MPN)
5'	WP10 (Immunophenotyping)
5'	WP11 (Cytogenetics)
5'	WP12/13 (MRD, NGS)
5'	WP14 (Transplantation)
5'	WP17 (Statistics)
17:30-17:45	ELN Merit Awards for long-term cooperative research on pregnancy in CML
15'	Ekaterina Chelysheva Elisabetta Abruzzese Jane Apperley
17:45 - 18:00	Break with Group photo
18:00 - 20:00	Session 15: Keynote lectures
20'	The 2022 ELN recommendations for treating AML
20'	Paradigm shift in diagnosis and treatment of MPN
20'	The benefit of health expenses
20'	ELN recommendations 2023 for immunophenotyping in MDS
20'	New EU platform for treating R/R AML
20:00	Working dinner in the foyer

C. Thiede, T. Haferlach, N. Cross

S. Maschek
J. Bartram
C. Thiede
TBC

Chairs/Contributors

M. Lauseker, J. Guilhot
M. Lauseker, J. Guilhot

J. Guilhot
M. Lauseker

T. Lang
M. Lauseker, J. Guilhot

R. Hehlmann, D. Niederwieser

R. Hehlmann
A. Hochhaus
G. Ossenkoppele
C. Röllig
J. Hernandez
D. Hoelzer
P. Ghia
L. Malcovati
T. Barbui
M. Béné
I. Summerer
T. Haferlach
D. Niederwieser
M. Lauseker

R. Hehlmann

Introducer: R. Gale

R. Hehlmann, D. Hoelzer

H. Döhner
H. Hasselbalch
W. März
T. Haferlach
G. Martinelli (TBC)

(TBC = to be confirmed)